Levitee Labs (CSE:LVT) Inc announced that it has formed a medical advisory board consisting of experts across a diverse group of fields, including addiction, mental health, drug development, compounding, chronic pain, policy, neurology, and psychedelics.
The Vancouver, British Columbia-based company said that it methodically recruited each member of the new medical advisory board for their individual expertise and cumulative synergies that will facilitate expeditious and efficient growth through connections to other thought leaders and major players in all relevant industries.
North Americans are faced with an ever-increasing crisis of mental health and addiction disorders that demand innovation to flatten and reverse the curve. Much like the United States, Canada suffered a 74% increase in opioid-related deaths over the course of the first six months of the coronavirus (COVID-19) pandemic.
READ: Levitee Labs collaborates with LiveRx Research to test, treat and cure Hepatitis C; provide equitable access throughout Alberta, Canada
“Providing effective, easily accessible treatment options to the millions of people suffering from substance abuse disorder is the foundation of our strategy and I am confident in the contributions the medical advisory board will make to meet all our goals by changing the existing paradigm," said Pouya Farmand, CEO at Levitee Labs (CSE:LVT) (Levitee Labs (CSE:LVT)) in a statement.
"Our strategy is solid, and our team is unparalleled, a combination that points to a bright future where negative addiction stigmas are removed and instead of feeling hopeless, patients readily get the help and support they need to overcome their difficult disorders," he added.
Levitee’s medical advisory board consists of five members — Mark Tarnopolsky, Noha ElSayed, Bakir Al Tikriti, Mohammed Mosli, and Eding Mvilongo.
Tarnopolsky is a professor of pediatrics and is division head of Neuromuscular and Neurometabolic Diseases at McMaster University Children’s Hospital, Hamilton, Ontario. In addition to extensive research efforts into the diagnosis and therapeutic options for these disorders, he has published over 500 PubMed articles with an h-index of 130.
ElSayed earned her bachelor of science degree in pharmacy and obtained her additional prescribing authorities from The Alberta College of Pharmacists. She is an active member of several specialized health care networks. ElSayed has a passion for mental health care, addiction treatment, custom compounding, and travel health, as well as diabetes and chronic disease management education.
Al Tikriti is an addiction medicine and chronic pain management specialist. He deals with complex addiction and mental health cases and medical management for chronic pain complex patients.
Mosli is a multilingual public health and preventive medicine physician specialized in addictions health, health services improvement, health promotion, environmental public health, and health policy. He has spent the last five years as a Medical Officer of Canada’s largest province-wide, fully-integrated health system that serves over four million patients
Eding Mvilongo is an anesthesiologist working in Montréal, Québec. Mvilongo is currently practicing at Hôpital Cité-de-la-Santé and is affiliated with Hôpital Sainte-Justine, a major Pediatric Center in Québec.
Through the acquisition of clinics, pharmacies, and leading technologies, Levitee Labs (CSE:LVT) is re-imagining the treatment dynamic and taking a holistic approach to bridge the gaps in therapeutic programs today. In November, the Company signed a letter of intent (LOI) to acquire 51% of a compounding pharmacy in Calgary, Alberta, Canada that will be used as an initial base for the production and distribution of pharmaceutical products, which will include pain and depression management products, such as ketamine.
Contact Ritika at ritika@proactiveinvestors.com